Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Invion Advances Skin Cancer Trial After Promising Early Results

Invion Limited (IVX) · Health care

IVX: $0.037 +0.00% · MC: $4M

Invion says preliminary results from 14 patient readouts in its completed Phase I non-melanoma skin cancer trial showed no treatment-related adverse events or dose-limiting toxicities and a 79% disease control rate, supporting progression to Phase II; final results await 12-month follow-up and independent audit. Two multi-year financing arrangements are expected to cover up to approximately 85% of current and future clinical development costs, while a new preclinical collaboration will test Photosoft with Percheron Therapeutics’ immunotherapy. Quarter-end cash was approximately $512,000, down from approximately $592,000 in the previous quarter.

Source announcements: 2026-10-29 09:03 to 2026-10-29 09:03 Sydney time
Story updated 2026-10-29 09:08 Sydney time
SourcesAppendix 4C and Quarterly Activities Report - September 2026
Comments